Immunic (IMUX) News Today $0.92 +0.02 (+1.99%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Immunic's (IMUX) Buy Rating Reiterated at D. Boral CapitalApril 13 at 4:03 AM | americanbankingnews.comD. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)D. Boral Capital restated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a report on Thursday.April 12 at 10:59 AM | marketbeat.comEQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | markets.businessinsider.comImmunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | prnewswire.comEQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 10, 2025 | markets.businessinsider.comImmunic sells 5.67M shares at 90c in registered direct offeringApril 10, 2025 | markets.businessinsider.comImmunic announces pricing of $5.1M direct offering to support clinical pipelineApril 9, 2025 | proactiveinvestors.comImmunic announces pricing of $5.1M direct offering to support clinical pipelineApril 9, 2025 | proactiveinvestors.comImmunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen InvestmentsApril 9, 2025 | prnewswire.comWhat is Leerink Partnrs' Forecast for Immunic Q1 Earnings?Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at Leerink Partnrs decreased their Q1 2025 earnings per share (EPS) estimates for Immunic in a report released on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now anticipates that the company will earn ($0.25) per share fApril 6, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook of Immunic Q1 EarningsApril 5, 2025 | americanbankingnews.comImmunic's (IMUX) "Buy" Rating Reaffirmed at D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $17.00 price target on shares of Immunic in a report on Tuesday.April 2, 2025 | marketbeat.comEQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in AprilApril 1, 2025 | markets.businessinsider.comImmunic, Inc. to Participate in Scientific and Industry Conferences in AprilApril 1, 2025 | prnewswire.comImmunic (IMUX) Has a New Rating from William BlairMarch 30, 2025 | markets.businessinsider.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from BrokeragesImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two have given a strong buy recoMarch 29, 2025 | marketbeat.comWilliam Blair Forecasts Immunic FY2026 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at William Blair issued their FY2026 earnings estimates for Immunic in a note issued to investors on Monday, March 24th. William Blair analyst M. Minter anticipates that the company will earn ($0.98) per share for the year. WilliamMarch 28, 2025 | marketbeat.comBrokers Set Expectations for Immunic FY2025 EarningsImmunic, Inc. (NASDAQ:IMUX - Free Report) - Research analysts at William Blair issued their FY2025 earnings estimates for shares of Immunic in a note issued to investors on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.89) for theMarch 27, 2025 | marketbeat.comImmunic Sees Unusually High Options Volume (NASDAQ:IMUX)Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders bought 2,229 call options on the company. This is an increase of approximately 849% compared to the typical volume of 235 call options.March 26, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Coverage Initiated by Analysts at William BlairWilliam Blair began coverage on Immunic in a research note on Tuesday. They issued an "outperform" rating for the company.March 26, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Immunic (IMUX) with Outperform RecommendationMarch 26, 2025 | msn.comStockNews.com Downgrades Immunic (NASDAQ:IMUX) to SellStockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a research report on Thursday.March 20, 2025 | marketbeat.comImmunic management to meet virtually with Piper SandlerMarch 18, 2025 | markets.businessinsider.comImmunic provides MS research update – ICYMIMarch 14, 2025 | proactiveinvestors.comImmunic provides MS research update – ICYMIMarch 14, 2025 | proactiveinvestors.comImmunic (NASDAQ:IMUX) Upgraded by StockNews.com to Hold RatingStockNews.com upgraded Immunic from a "sell" rating to a "hold" rating in a report on Wednesday.March 13, 2025 | marketbeat.comImmunic (IMUX) to Release Quarterly Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Sees Significant Decline in Short InterestImmunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 2,550,000 shares, a decrease of 32.0% from the January 31st total of 3,750,000 shares. Based on an average daily volume of 933,800 shares, the short-interest ratio is presently 2.7 days.March 3, 2025 | marketbeat.comEQS-News: Immunic to Participate in Scientific and Investor Conferences in MarchMarch 3, 2025 | markets.businessinsider.comImmunic to Participate in Scientific and Investor Conferences in MarchMarch 3, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of "Buy" from AnalystsShares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have received an average rating of "Buy" from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have given a strong buyMarch 3, 2025 | marketbeat.comBiotechs challenge big pharma with new oral weight loss therapiesFebruary 28, 2025 | proactiveinvestors.comEQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple SclerosisFebruary 26, 2025 | markets.businessinsider.comImmunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forumFebruary 26, 2025 | proactiveinvestors.comImmunic (NASDAQ:IMUX) Earns Buy Rating from D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $17.00 target price on shares of Immunic in a report on Wednesday.February 26, 2025 | marketbeat.comImmunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple SclerosisFebruary 26, 2025 | prnewswire.comImmunic (IMUX) Projected to Post Quarterly Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 25, 2025 | marketbeat.comB.Riley Financial Sticks to Their Buy Rating for Immunic (IMUX)February 24, 2025 | markets.businessinsider.comImmunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last weekFebruary 22, 2025 | finance.yahoo.comImmunic drug candidate may offer new obesity treatment - ICYMIFebruary 22, 2025 | proactiveinvestors.comImmunic's (IMUX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Immunic in a research report on Friday.February 22, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Lowered to Sell Rating by StockNews.comStockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a report on Saturday.February 22, 2025 | marketbeat.comD. Boral Capital Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)D. Boral Capital reaffirmed a "buy" rating and issued a $17.00 target price on shares of Immunic in a report on Thursday.February 21, 2025 | marketbeat.comImmunic highlights IMU-856's potential as weight management therapyFebruary 20, 2025 | proactiveinvestors.comImmunic announces IMU-856 demonstrated dose-dependent increaseFebruary 20, 2025 | markets.businessinsider.comImmunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical TestingFebruary 20, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Short Interest UpdateImmunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 3,750,000 shares, an increase of 6.5% from the January 15th total of 3,520,000 shares. Based on an average trading volume of 925,600 shares, the short-interest ratio is currently 4.1 days.February 19, 2025 | marketbeat.comIMUX stock touches 52-week low at $0.92 amid market challengesFebruary 12, 2025 | msn.comImmunic (NASDAQ:IMUX) Rating Lowered to Sell at StockNews.comStockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research note on Monday.February 10, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by BrokeragesShares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been assigned an average recommendation of "Buy" from the eight ratings firms that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and two have assigned a strFebruary 6, 2025 | marketbeat.com Remove Ads Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.280.80▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼113▲IMUX Articles Average Week Remove Ads Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Phathom Pharmaceuticals News Cartesian Therapeutics News REGENXBIO News Allogene Therapeutics News Oruka Therapeutics News Benitec Biopharma News Entrada Therapeutics News Heron Therapeutics News Alpha Teknova News Mereo BioPharma Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMUX Stock Free IMUX Stock Alerts